Inhibikase Therapeutics Q1 2024 GAAP EPS $(0.73) Beats $(0.79) Estimate, Cash $9.7M
Portfolio Pulse from Benzinga Newsdesk
Inhibikase Therapeutics (NASDAQ:IKT) reported a Q1 2024 GAAP EPS of $(0.73), beating the analyst estimate of $(0.79). This represents a 25.51% improvement over the same period last year. The company has $9.7M in cash.
May 16, 2024 | 7:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibikase Therapeutics reported a Q1 2024 GAAP EPS of $(0.73), beating the analyst estimate of $(0.79) and showing a significant improvement over the same period last year. The company has $9.7M in cash.
The better-than-expected EPS and significant year-over-year improvement are positive indicators for the stock. The company's cash position of $9.7M also provides a cushion for future operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100